$0

Thoughts on TCR2 Tx’s Collaboration With BMS

On Monday, October 25, TCR2 Therapeutics announced (press release) a clinical trial collaboration with BMS to evaluate gavo-cel (TC-210; mesothelin TRuC-T) with Opdivo (nivolumab; PD1 inhibitor) ± Yervoy (ipilimumab; CTLA-4 inhibitor) in a Ph2 trial for refractory mesothelin-expressing solid tumors. Below, Celltelligence provides insights on why TCR2 Tx may have chosen BMS’s checkpoint inhibitors and how BMS could leverage this collaboration for their own solid tumor programs.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.